Neogenomics Inc Stock Price, News & Analysis

NeoGenomics (NASDAQ: NEO) reported Q2 2025 results with consolidated revenue increasing 10% to $181 million. Clinical revenue grew 16%, with 13% growth excluding the Pathline acquisition. The company's average revenue per clinical test increased 2% to $465, driven by higher-value tests and strategic reimbursement initiatives.

Despite revenue growth, NEO reported a net loss of $45 million, up 142% year-over-year, primarily due to $20 million in impairment charges. Adjusted EBITDA remained relatively flat at $10.7 million. The company completed the acquisition of Pathline for $8 million plus contingent consideration.

NeoGenomics revised its full-year 2025 guidance downward, now expecting revenue of $720-726 million (9-10% growth) and increased net loss projections to $108-116 million, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch.

NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its second quarter 2025 financial results announcement for July 29, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and recent highlights.

Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants can dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 859170.

NeoGenomics (NASDAQ: NEO) has launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, along with PanTracer Tissue + HRD option for enhanced tumor analysis. The new assay evaluates over 500 cancer-related genes and can deliver results in as little as 8 days.

PanTracer Tissue + HRD specifically targets ovarian cancer diagnostics by incorporating homologous recombination deficiency analysis, BRCA mutation status, and genomic instability score in a single test. These biomarkers are crucial for guiding PARP inhibitor treatments and therapies targeting DNA repair pathways.

The new offerings, revealed at the 2025 ASCO Annual Meeting, represent an upgrade to the company's previous NeoComprehensive® Solid Tumor platform, featuring minimal specimen requirements and alignment with clinical guidelines for therapy selection and clinical trial enrollment.

NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has appointed Dr. Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green currently serves as Senior Vice President and Head of Oncology, Global Clinical Development at Merck, overseeing the company's largest commercial revenue and pipeline investment area.

Dr. Green brings extensive experience in clinical oncology and pipeline development, having previously held leadership positions at Seagen and Genentech. She began her career as a Medical Oncologist at MD Anderson Cancer Center, where she later became Medical Director of the Nellie B. Connally Breast Center.

NeoGenomics (NASDAQ:NEO) is set to unveil its PanTracer™ Family of genomic profiling tests and Paletrra™ spatial proteomics platform at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3, 2025). The PanTracer suite includes three tests: PanTracer™ Tissue for comprehensive tumor profiling, PanTracer™ LBx for liquid biopsy applications, and PanTracer™ Tissue + HRD for homologous recombination deficiency testing.

Paletrra, an AI-powered platform, transforms tissue samples into high-plex, image-based insights for translational research teams. The company will showcase these solutions at Booth #11093, featuring an interactive "Hey Neo" experience. Additionally, NeoGenomics will present research findings through one poster presentation and two online abstracts, focusing on folate receptor alpha expression, cancer fusionome analysis, and PanTracer LBx validation.

NeoGenomics (NASDAQ:NEO), a leading oncology testing services company, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 1:00 pm ET, followed by a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4 at 2:00 pm ET. Both sessions will be available via webcast, accessible through the company's Investor Relations website at ir.neogenomics.com.

NeoGenomics (NASDAQ: NEO), an oncology testing services provider, has announced the complete repayment of its $201.25 million outstanding 1.25% Convertible Senior Notes that were due to mature on May 1, 2025. The company utilized its available cash reserves to fully settle this debt obligation.

NeoGenomics and Ultima Genomics have announced a strategic collaboration to enhance cancer diagnostic capabilities using the UG 100 sequencing platform. NeoGenomics has purchased and will install the UG 100 sequencer at their Cambridge, UK innovation center.

The collaboration leverages Ultima's ppmSeq™ technology, which offers cost-effective and low-error sequencing. Recent improvements through the Solaris portfolio have achieved 5x yield improvements, enabling 30X coverage from just 2 nanograms of DNA - a significant advancement for liquid biopsy applications.

This partnership aims to advance oncology diagnostic solutions, particularly in areas like minimal residual disease (MRD) detection and whole genome sequencing. The UG 100 platform's unique architecture specifically addresses the needs of large-scale, cost-effective applications while maintaining high accuracy for early cancer detection.

NeoGenomics reported strong Q1 2025 results with consolidated revenue increasing 8% to $168 million. The oncology diagnostics provider saw its net loss decrease by 4% to $26 million, while Adjusted EBITDA showed remarkable growth of 102% to reach $7 million.

Key performance metrics include:

• Average revenue per clinical test rose 3% to $459
• Consolidated gross profit increased 12% to $73 million
• Gross profit margin reached 44%
• Cash and marketable securities totaled $358 million

The company revised its full-year 2025 guidance to include $12-14 million additional revenue from the Pathline acquisition. Updated projections show consolidated revenue between $747-759 million, representing 13-15% year-over-year growth. Management expects continued acceleration through portfolio expansion and enhanced customer experience.